Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardio-Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.

Journal of the American Heart Association·2026

Same author

Even mild elevations of C-reactive protein levels predict long-term prognosis in heart failure with mildly reduced ejection fraction.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Same author

Association Between Predicting Risk of Cardiovascular Disease Events (PREVENT) Risk Scores and Subclinical Cardiovascular Disease: Insights From the Project Baseline Health Study.

Journal of the American Heart Association·2026

Same author

Dynamic changes in mean corpuscular volume could be integrated into longitudinal prediction frameworks for individualized risk assessment in the ICU setting: A retrospective study.

Science progress·2026

Same author

Global survey of women's awareness of pregnancy- and postpartum-associated venous thromboembolism (World Thrombosis Day 2025).

Research and practice in thrombosis and haemostasis·2026

Same author

Cost of illness of type 2 diabetes mellitus with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis.

BMC health services research·2026

Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026

Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026

Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026

Same journal

Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.

Clinical and translational science·2026

Same journal

Correction to "Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient ith the NUDT15 1/6 Genotype: A Brief Report".

Clinical and translational science·2026

Same journal

Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

Clinical and translational science·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 20, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI.

Diona Gjermeni¹, Sofia Szabó¹, Viktoria Anfang¹

¹Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Clinical and Translational Science

|May 19, 2026

Summary

This summary is machine-generated.

CYP2C19 genetic variations did not increase ischemic risk in atrial fibrillation patients undergoing PCI. However, poor/intermediate metabolizers showed a trend towards reduced bleeding, while low platelet reactivity was linked to major bleeding events.

Keywords:

atrial fibrillation cytochrome P450 2C19 percutaneous coronary intervention platelet aggregation platelet function testing

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: May 20, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Pharmacogenomics
Cardiovascular Medicine
Clinical Thrombosis

Background:

CYP2C19 genetic polymorphisms influence clopidogrel's antiplatelet effect.
This impacts ischemic and bleeding risks in patients undergoing percutaneous coronary intervention (PCI).
Atrial fibrillation (AF) patients on oral anticoagulation (OAC) and clopidogrel require careful risk assessment.

Purpose of the Study:

To evaluate the association of CYP2C19 genotype and platelet reactivity (PR) with ischemic and bleeding risks.
Focus on AF patients undergoing PCI treated with OAC and clopidogrel.
Assess outcomes including death, myocardial infarction (MI), stroke, and bleeding events.

Main Methods:

Two-center prospective cohort study of 283 AF patients on OAC undergoing PCI.
Classified patients into poor/intermediate metabolizers (PM/IM) and rapid metabolizers (RM) based on CYP2C19 LOF/GOF alleles.
Assessed PR using thromboelastography (TEG) and/or multiple electrode aggregometry (MEA).

Main Results:

PM/IM status (26%) was not significantly associated with the primary ischemic outcome (8.2% vs. 7.6%, p=0.869).
Bleeding rates were numerically lower in PM/IM patients.
High platelet reactivity (HPR) showed a trend towards increased ischemic risk (OR 2.005), while low platelet reactivity (LPR) was associated with major bleeding (OR 2.646, p=0.034).

Conclusions:

CYP2C19 PM/IM status did not increase ischemic risk in this AF patient cohort.
PM/IM status may offer protection against bleeding risk in AF patients undergoing PCI.
HPR may indicate higher ischemic risk, whereas LPR is linked to major bleeding events.